Should you buy PACS Group, Inc. at $46.91?
See what the price requires, what could disappoint, and how the purchase changes your exposure.
Price as of Oct 18, 2026, 4:30 PM UTC (polygon last daily bar) · Financial evidence through Nov 19, 2025
Inspect the public analysis below, or continue directly with your own investment case.
What has to happen for the investment to work?
The selected assumptions produce $38.87–$87.20 per share. Discount rate explains the largest part of that range. Test it below.
| Investment driver | Reported evidence | Base-case assumption | What the price requires |
|---|---|---|---|
| Revenue growth | Trailing 4-year revenue CAGR of -1.3%, faded toward terminal growth over 5 years. | -1.29% | -8.33% |
| Cash margin | 9.4% trailing (Polygon vX financials) | Operating margin (steady-state): 4.03% | Implied steady-state FCF margin: 7.88% |
| Discount rate | CAPM baseline: 5.10% risk-free + β0.26 × 5.5% ERP = 6.51%. | 6.51% | Held fixed |
Compare the cases before committing capital.
| Downside | Base | Upside | |
|---|---|---|---|
| Free cash flow vs stored forecast | −15% | Stored | +15% |
| Discount rate | 7.51% | 6.51% | 5.51% |
| Calculated value per share | $38.87 | $56.94 | $87.20 |
| Difference from reference price | -17.1% | +21.4% | +85.9% |
| Main condition | Cash generation disappoints and capital costs more | Stored forecast holds | Cash generation beats and capital costs less |
These are conditional valuation results. Each case's assumptions are listed in the table.
What would the purchase mean for you?
Investigate the assumption with the largest effect.
Changing discount rate from 6.51% to 7.51% changes the calculated value from $56.94 to $45.61.
The supporting evidence is CAPM baseline: 5.10% risk-free + β0.26 × 5.5% ERP = 6.51%..
Keep this buying case under review.
Save your proposed investment, selected assumptions, and scenarios. Choose the developments that should reopen the decision, then return to the same case when the evidence changes.
What could change the conclusion?
No dated development in the last 45 days points against this position.
Next relevant disclosure or review condition: Re-underwrite if revenue growth, margins, or the cost of capital diverge materially from the stored assumptions. (last filing Nov 19, 2025).
Should I sell?Should I hold?Should I hedge?How to hedgeImpact ledger